NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
1.030
-0.008 (-0.77%)
May 2, 2025, 4:00 PM EDT - Market closed

NeuroSense Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-10.21-10.11-10.49-3.22-2.83
Upgrade
Depreciation & Amortization
0.020.020.0100
Upgrade
Loss (Gain) From Sale of Assets
---0.01-
Upgrade
Stock-Based Compensation
0.561.541.731.222.06
Upgrade
Other Operating Activities
0.28-1.720.040.18-0
Upgrade
Change in Accounts Receivable
-----0.01
Upgrade
Change in Accounts Payable
-0.30.960.46-0.020.03
Upgrade
Change in Other Net Operating Assets
-0.480.950.640.290.05
Upgrade
Operating Cash Flow
-10.14-8.35-7.62-1.54-0.7
Upgrade
Capital Expenditures
-0-0.03-0.07-0.02-0.01
Upgrade
Investment in Securities
03.5-3.52--
Upgrade
Investing Cash Flow
03.47-3.59-0.02-0.01
Upgrade
Issuance of Common Stock
11.34.343.8711.90.51
Upgrade
Other Financing Activities
-0.39-0.36-0.1--
Upgrade
Financing Cash Flow
10.913.983.7711.90.51
Upgrade
Foreign Exchange Rate Adjustments
-0.040.01-0.090.02-
Upgrade
Net Cash Flow
0.74-0.9-7.5210.36-0.2
Upgrade
Free Cash Flow
-10.14-8.38-7.69-1.56-0.7
Upgrade
Free Cash Flow Per Share
-0.55-0.61-0.67-0.25-0.13
Upgrade
Levered Free Cash Flow
-7.83-4.26-3.8-0.470.28
Upgrade
Unlevered Free Cash Flow
-7.83-4.26-3.8-0.470.28
Upgrade
Change in Net Working Capital
2.22-1.74-1.12-0.2-0.03
Upgrade
Updated Dec 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q